Kyle Munz

Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.

The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.

As a growing number of young adults with primary liver cancer (PLC) related to metabolic dysfunction–associated steatohepatitis (MASH) age, developing coherent strategies to combat the metabolic disease epidemic is critical.

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

A new meta-analysis adds to the body of literature promoting the benefits of exercise for patients with cancer.

With a majority vote by the Senate Finance Committee, Robert F. Kennedy Jr's nomination for health secretary is pushed to a vote from the full Senate.

A polypill for preventing cardiovascular disease has the potential to address health inequities and expand health care access for low-income populations.

A looming Supreme Court ruling will answer questions about the legality of the Affordable Care Act mandate for providing some preventive care services at no cost.

The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper research considerations.

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney disease risks.

The investigators believe their decades-spanning analysis underscores the need to address access barriers to anti-obesity therapeutics.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy at Minnesota Oncology, discusses how the prospect of patient longevity, amidst advancing therapeutics, factors into oncology care.

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 receptor agonist (GLP-1RA) could see their liver health improve with the addition of efruxifermin.

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).

Analyzing patients' travel time to receive emergency surgical services provides valuable insights that can inform policy reform and address the needs of rural communities.

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.

Peptidomics offered new diagnostic insights into the underlying processes of metabolic dyfunction-associated steatotic liver disease (MASLD).

Patient outcomes appeared to be more heavily driven by breast cancer stage than delays in diagnosis, researchers found.

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.

Here are 5 things individuals should know about the powerful impact of blood donation and the benefits becoming a donor can have for patients in need.

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA vaccines could bolster immunity in this vulnerable population.

Data pulled from the impact of Clinical Resource Hubs (CRHs) demonstrate the benefits these programs provide to veterans who may be experiencing gaps in care.

Opioid use disorder (OUD) can cause serious maternal complications, but data on the burden of OUD in pregnancy is severely lacking and more evidence-based solutions are needed.

Tim Mok, PharmD, BCPS, BCOP, malignant hematology pharmacy research analyst at Kaiser Permanente, discussed his perspective on the balance between clinical outcomes and cost considerations.

Song Park, MD, University of Washington Medicine, advocates for more user-friendly technology to support equitable skin cancer care access.

Sara Grethlien, MD, MBA, FACP, Swedish Cancer Institute, looks ahead to the future of oncology care and important value-based care considerations.

The most-viewed pieces of multiple sclerosis (MS) content covered remeylination therapies, the potential of cannabis treatment, potential predictors of MS, and reliable telemedicine developments.